NYMC Faculty Publications
Lack of Genotoxicity Potential and Safety Assessment of 4-(2-Hydroxyethyl) Morpholine Present as an Impurity in Pharmaceuticals and Nutritional Supplements
Author Type(s)
Faculty
Journal Title
Food and Chemical Toxicology
First Page
114352
Document Type
Article
Publication Date
2-1-2024
Department
Pathology, Microbiology and Immunology
Abstract
4-(2-Hydroxyethyl) morpholine (HEM) is widely used as a building block of macromolecules in the manufacture of pharmaceuticals and dietary supplements and could remain as an impurity in the finished products. An evaluation of HEM was conducted to identify endpoints that could be used to determine the point-of-departure (POD) for use in assessing the potential risk from exposure to HEM. No oral repeated dose toxicological studies of appropriate duration were found for HEM. Therefore, suitable analogue(s) were identified. Although oral repeated dose studies were available for the analogues, the studies were not of sufficient duration for use in the assignment of a POD for risk evaluation. Accordingly, the Threshold of Toxicological Concern (TTC) approach, which proposes that a de minimis value can be derived to qualitatively assess risk, was considered for HEM. To determine the appropriate TTC approach (genotoxic or non-genotoxic), the genotoxicity of HEM and its analogues were evaluated. The weight of the evidence indicated that HEM, and the appropriate analogues, are not genotoxic. Considering the chemical structure of HEM, the non-genotoxic Cramer class III TTC value of 1.5 μg/kg bw/day was determined to be appropriate for use in safety assessment of HEM as an impurity in products intended for human consumption.
Recommended Citation
Thiffault, C., Freeman, E. L., Williams, G. M., & Tran, N. L. (2024). Lack of Genotoxicity Potential and Safety Assessment of 4-(2-Hydroxyethyl) Morpholine Present as an Impurity in Pharmaceuticals and Nutritional Supplements. Food and Chemical Toxicology, 184, 114352. https://doi.org/10.1016/j.fct.2023.114352
